You are here: Industry Insights > Lenvima

News List

Japan approves Keytruda plus Lenvima combination for endometrial cancer treatment drugs
December 28, 2021
the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Keytruda plus Lenvima combination to treat endometrial carcinoma.
European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma AmericanPharmaceuticalReview
December 02, 2021
Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance...
EC grants approval for Merck-Eisai’s combo therapy for endometrial cancer Pharmaceutical-Technology
December 01, 2021
The European Commission (EC) has granted approval for Merck (MSD) and Eisai’s Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) to treat adults with advanced or recurrent endometrial cancer.
FDA approves Keytruda plus Lenvima for advanced kidney cancer pharmatimes
August 13, 2021
The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult patients with advanced renal cell carcinoma ...
US clears Keytruda, Lenvima combo in first-line kidney cancer firstwordpharma
August 12, 2021
The FDA announced Wednesday that it approved the combination of Merck & Co.'s anti-PD-1 therapy Keytruda (pembrolizumab) and Eisai's oral multi-kinase inhibitor Lenvima (lenvatinib) as a first-line treatment for adults with advanced renal cell carcinoma.
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma drugs
July 29, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima.
Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer contractpharma
July 26, 2021
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
Eisai’s anti-cancer agent LENVIMA receives orphan drug designation pharmaceutical-technology
March 16, 2021
Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer.
Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial pharmaceutical-business-review
December 21, 2020
Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai ..
Lenvima plus Keytruda achieves primary endpoints in trial for RCC europeanpharmaceuticalreview
November 12, 2020
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.

Previous page 1 2 3 Next page